Novocure Ltd (NVCR) P/E Ratio History
Deep ValueTrading at -12.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2021
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, Novocure Ltd (NVCR) trades at a price-to-earnings ratio of -12.2x, with a stock price of $14.94 and trailing twelve-month earnings per share of $-1.28.
The current P/E is 102% below its 5-year average of 794.1x. Over the past five years, NVCR's P/E has ranged from a low of 494.2x to a high of 1203.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, NVCR trades at a 153% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, NVCR trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NVCR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NVCR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NVCR P/E vs Peers
Patient monitoring and respiratory care peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.2Lowest | 0.60Best | +817%Best | |
| $3B | 8.7 | - | +68% | |
| $41B | 39.6 | 2.77 | +23% | |
| $17B | 30.5 | - | -25% | |
| $810M | 9.9 | 0.99 | -36% | |
| $111B | 23.2 | 3.31 | +3% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NVCR Historical P/E Data (2020–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q1 | Mar 31 2021 | $132.18 | $0.11 | 1203.8x | +52% |
| FY2020 Q4 | - | $173.04 | $0.19 | 910.7x | +15% |
| FY2020 Q3 | Sep 30 2020 | $111.31 | $0.19 | 585.8x | -26% |
| FY2020 Q2 | - | $59.30 | $0.12 | 494.2x | -38% |
| FY2020 Q1 | - | $67.34 | $0.09 | 775.8x | -2% |
Average P/E for displayed period: 794.1x
NVCR Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NVCR — Frequently Asked Questions
Quick answers to the most common questions about buying NVCR stock.
What is NVCR's P/E ratio?
Novocure Ltd (NVCR) trailing twelve-month P/E ratio is -12.2x, based on TTM diluted EPS of $-1.28. The 5-year average P/E is 794.1x and the historical range spans 494.2x to 1203.8x.
Is NVCR stock overvalued or undervalued?
NVCR trades at -12.2x P/E, below its 5-year average of 794.1x. At the 0th percentile of its historical range (494.2x–1203.8x), the stock is priced at a discount to its own history.
Is NVCR stock expensive?
No, NVCR is not expensive on a historical basis. The current P/E of -12.2x is below the 5-year average of 794.1x and sits at the 0th percentile of its valuation range.
What is NVCR's historical P/E range?
Over the past 5 years, NVCR's P/E ratio has ranged from 494.2x to 1203.8x, with a median of 775.8x and an average of 794.1x. The current P/E of -12.2x places the stock at the 0th percentile of this range. Full historical data spans 2020–2021.
How does NVCR's P/E compare to the S&P 500?
NVCR trades at -12.2x P/E versus the S&P 500 median of 24.5x. The 150% discount to the market suggests lower growth expectations or perceived higher risk.
How does NVCR's valuation compare to Healthcare peers?
Novocure Ltd P/E of -12.2x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NVCR's PEG ratio?
NVCR PEG ratio is N/A, based on a P/E of -12.2x and EPS growth of 21.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NVCR's earnings yield?
NVCR earnings yield is N/A, the inverse of its -12.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.